News & Press
BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Data Showing Over 80% Remission Rate
investors.brainsway.com6/9/2026·06/09/26🌐 Global
Summary
BrainsWay presented preliminary 12-month data for its SWIFT accelerated Deep TMS protocol, reporting more than 80% remission one year after treatment and a drop in severe functional impairment from 85% to 0%. The results suggest durable antidepressant effects from accelerated Deep TMS and support broader adoption of neuromodulation-based interventions in treatment-resistant depression.
Why it matters
Twelve-month durability data strengthens the clinical case for accelerated Deep TMS, addressing a key payer concern that faster protocols might sacrifice long-term efficacy. Sustained remission rates support broader insurance coverage and wider adoption in depression treatment.
#TMS#Neuromodulation#Depression#Clinical Trial#FDA Approved
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in